Bavarian Nordic Attracts Strong Acquisition Interest from Offeror
Bavarian Nordic A/S (OMX: BAVA) recently announced a significant development in its growth trajectory. The company has engaged in a strategic agreement with Innosera ApS, which is backed by Nordic Capital and Permira. This newly formed entity will initiate an all-cash voluntary public takeover offer, aiming to acquire all outstanding shares of Bavarian Nordic.
Details of the Acquisition Offer
The Offeror proposes a cash price of DKK 233 per share, leading to a potential valuation of approximately DKK 19 billion for Bavarian Nordic based on its fully diluted shares. Notably, this offer reflects a generous premium of 21% over the closing price prior to the announcement, indicating a strong commitment to ensuring value for shareholders.
Shareholder Premiums and Historical Pricing
The proposed offer price presents a compelling opportunity for shareholders, with premiums based on various historical share prices. Specifically, the DKK 233 per share represents a 31% premium over the one-month average share price leading up to the announcement, 35.5% over three months, and 37.4% over six months. This suggests that the Offeror values Bavarian Nordic's current position and future potential very highly.
Board of Directors’ Recommendation
Bavarian Nordic’s Board of Directors has carefully reviewed the proposal and, following due diligence, is poised to recommend that shareholders accept the offer when formally submitted. The Board's positive assessment is based on fairness opinions provided by their financial advisors, which affirmed the financial merit of the proposed offer.
Strategic Growth and Future Vision
Nordic Capital and Permira are convinced that this acquisition enables Bavarian Nordic to accelerate its strategic initiatives while maintaining a focus on public health and vaccine development. Their experience in scaling healthcare businesses is expected to bolster Bavarian Nordic’s mission of delivering innovative vaccine solutions globally. The Offeror highlights a vision centered on enhancing long-term shareholder value and expanding the company’s commercial reach.
Commitment to Public Health
The strategic partners emphasize their intent to continue operations at Bavarian Nordic’s primary facilities in cooperation with management and employees. They aim to advance the company’s ability to produce life-saving vaccines, reflecting a dedicated approach to public health challenges.
Offer Conditions and Timeline
The completion of the acquisition is contingent upon obtaining necessary regulatory approvals and acceptance from a significant majority of shareholders. The Offeror anticipates that, pending successful negotiations, the offer could lead to a delisting from Nasdaq Copenhagen and a proposed compulsory acquisition of remaining shares, which signifies a robust and decisive plan for Bavarian Nordic’s future.
Financial Advisors and Contacts
In collaboration with the ongoing acquisition process, Citi and Nordea have been selected as financial advisors to guide Bavarian Nordic. They bring an extensive understanding of market dynamics and valuation strategies critical to navigating this acquisition.
For investor inquiries in Europe, Rolf Sass Sørensen, Vice President of Investor Relations, can be contacted at rss@bavarian-nordic.com, and for US issues, Graham Morrell of Gilmartin Group at graham@gilmartinir.com is available for further assistance.
Frequently Asked Questions
What is the purpose of the acquisition offer?
The acquisition offer aims to transition Bavarian Nordic into a privately held company with enhanced resources for growth and strategic initiatives in the vaccine market.
Who are the financial advisors involved?
The financial advisors assisting Bavarian Nordic during this acquisition process are Citi and Nordea, both of whom are recognized in the finance industry.
What does the offer price reflect about Bavarian Nordic’s value?
The offer price of DKK 233 per share suggests a strong valuation of Bavarian Nordic, reflecting positive sentiment about the company’s future potential and market position.
What will happen if the offer is successful?
If the offer is successful, Bavarian Nordic intends to be delisted from Nasdaq Copenhagen, and the Offeror will initiate a compulsory acquisition of remaining shares.
How does this acquisition affect Bavarian Nordic’s employees?
The Offeror intends to maintain operational continuity and work closely with existing management and staff to support the company’s growth goals.
